Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The Current and Future Therapies for Human Osteosarcoma.

Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH.

Curr Cancer Ther Rev. 2013 Feb;9(1):55-77.

2.

Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR.

JAMA Oncol. 2016 Feb;2(2):201-8. doi: 10.1001/jamaoncol.2015.4398.

3.

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE.

Br J Cancer. 2015 Nov 3;113(9):1282-8. doi: 10.1038/bjc.2015.351. Epub 2015 Oct 13.

4.

Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.

Wang B, Tu J, Yin J, Zou C, Wang J, Huang G, Xie X, Shen J.

Oncotarget. 2015 Nov 10;6(35):38348-59. doi: 10.18632/oncotarget.5276.

5.

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study.

Ogura K, Fujiwara T, Yasunaga H, Matsui H, Jeon DG, Cho WH, Hiraga H, Ishii T, Yonemoto T, Kamoda H, Ozaki T, Kozawa E, Nishida Y, Morioka H, Hiruma T, Kakunaga S, Ueda T, Tsuda Y, Kawano H, Kawai A.

Cancer. 2015 Nov 1;121(21):3844-52. doi: 10.1002/cncr.29575. Epub 2015 Jul 20.

6.

Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.

Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X.

Chin Med J (Engl). 2015 Jan 5;128(1):111-8. doi: 10.4103/0366-6999.147829.

7.

Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy.

Xu M, Xu SF, Yu XC.

Curr Oncol. 2014 Oct;21(5):e678-84. doi: 10.3747/co.21.1973.

8.

Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma.

Lin F, Juan Y, Zheng SE, Shen Z, Tang LN, Zhao H, Yao Y.

Curr Ther Res Clin Exp. 2009 Apr;70(2):150-60. doi: 10.1016/j.curtheres.2009.04.005.

9.

Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.

Scott JR, Ward DA, Crews KR, Panetta JC, Navid F.

Pediatr Blood Cancer. 2014 Feb;61(2):373-5. doi: 10.1002/pbc.24741. Epub 2013 Aug 19.

10.

Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.

Rühs H, Becker A, Drescher A, Panetta JC, Pui CH, Relling MV, Jaehde U.

PLoS One. 2012;7(9):e46015. doi: 10.1371/journal.pone.0046015. Epub 2012 Sep 25.

11.

Preoperative transarterial Embolisation in bone tumors.

Gupta P, Gamanagatti S.

World J Radiol. 2012 May 28;4(5):186-92. doi: 10.4329/wjr.v4.i5.186.

12.

Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Hagos Y, Wolff NA.

Toxins (Basel). 2010 Aug;2(8):2055-82. doi: 10.3390/toxins2082055. Epub 2010 Aug 9. Review.

13.

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.

McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M, Bramwell V, Lewis IJ, Taminiau AH, Nooij MA, Hogendoorn PC, Gelderblom H, Whelan JS.

Eur J Cancer. 2012 Mar;48(5):703-12. doi: 10.1016/j.ejca.2011.09.012. Epub 2011 Oct 27.

14.

Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines.

Otvös R, Skribek H, Kis LL, Gloghini A, Markasz L, Flaberg E, Eksborg S, Konya J, Gergely L, Carbone A, Szekely L.

BMC Cancer. 2011 Oct 12;11:441. doi: 10.1186/1471-2407-11-441.

15.

Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.

Guillon MA, Mary PM, Brugière L, Marec-Bérard P, Pacquement HD, Schmitt C, Guinebretière JM, Tabone MD.

BMC Cancer. 2011 Sep 24;11:407. doi: 10.1186/1471-2407-11-407.

16.

High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.

Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS.

Br J Clin Pharmacol. 2012 Jan;73(1):106-14. doi: 10.1111/j.1365-2125.2011.04054.x.

17.

Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM.

Cancer. 2011 Jun 15;117(12):2770-8. doi: 10.1002/cncr.25715. Epub 2011 Jan 10.

18.

Embolization of musculoskeletal bone tumors.

Owen RJ.

Semin Intervent Radiol. 2010 Jun;27(2):111-23. doi: 10.1055/s-0030-1253510.

19.

GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.

Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S, Wyatt P, Joel SP, Oliver RT.

Br J Cancer. 2007 Aug 6;97(3):308-14. Epub 2007 Jul 3. Erratum in: Br J Cancer. 2007 Oct 22;97(8):1188. Berney, Dan [added].

20.

Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E, Skribek H, Szekely L.

BMC Cancer. 2006 Nov 13;6:265.

Supplemental Content

Support Center